In vivo imaging of alkaline phosphatase in lipid metabolic diseases with a photoacoustic probe
Chun-Pu Mao,Xu-Yang Chen,Jie Han,Ting Jiang,Xiao-Xin Yan,Dong-Lin Hao,Jian-Hua Jin,Biao Yu,Jie-Li Zhou,Kai Wang,Li-Ting Zhang
DOI: https://doi.org/10.1016/j.saa.2024.125351
IF: 4.831
2024-11-01
Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy
Abstract:Lipid metabolic diseases have become an important challenge to global public health. Along with lifestyle changes, the incidence of obesity, diabetes and other metabolic syndromes is on the rise, and the number of patients with fatty liver disease is also increasing. Therefore, it is particularly important to develop effective lipid imaging strategies to monitor and manage fatty liver disease. Herein, based on the essential role of alkaline phosphatase (ALP) in both AS and OB, in vivo imaging of ALP was achieved in two lipid metabolic diseases models with a photoacoustic (PA) probe phosphorylated hemicyanine ( P-Hcy ). After being triggered by ALP, P-Hcy responded in different modalities including absorbance, fluorescence and, most significantly, PA-reporting. Notably, the PA signal showed the reliable linear correlation to the ALP level within the range of 0–800 U/L. The probe P-Hcy exhibited the advantages including high sensitivity, high selectivity, and steadiness in required biological conditions. The intracellular imaging results ensured that P-Hcy could visualize the ALP level in the foam cells induced from mouse mononuclear macrophages. In the healthy and lipid metabolic diseases models, P-Hcy was able to distinguish well between a lipid metabolic disease model and a healthy mouse model by photoacoustic imaging. By combining the ALP detection with P-Hcy in PA/fluorescence modality and traditional techniques such as blood biochemical testing and immunohistochemically staining, more potential strategy to accurately diagnose lipid metabolic diseases in the pre-clinical trials might be developed in future.
spectroscopy